Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: A potential factor contributing to HIV-associated accelerated aging

Journal of Infectious Diseases

Volumn 207, Issue 7, 2013, Pages 1157-1165

  Leeansyah, Edwin ^a,b   Cameron, Paul U ^a,b,c   Solomon, Ajantha ^a,b   Tennakoon, Surekha ^a,b   Velayudham, Pushparaj ^a,b   Gouillou, Maelenn ^b   Spelman, Tim ^b,d   Hearps, Anna ^a,b   Fairley, Christopher ^e   Smit, De Villiers ^f   Pierce, Anna B ^c   Armishaw, Jude ^c   Crowe, Suzanne M ^a,b   Cooper, David A ^g,h   Koelsch, Kersten K ^g,h   Liu, Jun Ping ^i,j   Chuah, John ^k,l,m   Lewin, Sharon R ^a,b,c  

^a MONASH UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

^c Infectious Diseases Unit   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^f Emergency and Trauma Centre   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k Gold Coast Sexual Health Clinic   (United States)

^l Holdsworth House Medical Practice   (Australia)

^m GRIFFITH UNIVERSITY   (Australia)

more..

Author keywords

aging; antiretroviral therapy; HIV infection; telomerase; telomere

Indexed keywords

ABACAVIR; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELOMERASE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ACCELERATED AGING; ADULT; AGING; ARTICLE; CELL ACTIVATION; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING;

ADENINE; ADULT; AGING; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CELLS, CULTURED; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; ENZYME ACTIVATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TELOMERASE; TELOMERE; TELOMERE SHORTENING; TIME FACTORS; YOUNG ADULT; ZIDOVUDINE;

EID: 84874746841     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit006     Document Type: Article

References (48)

1. Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60. (Pubitemid 28135961)
2. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
3. Collaboration ATC. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-96.
4. Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 2005; 579: 859-62. (Pubitemid 40361854)
5. Hodes RJ, Hathcock KS, Weng NP. Telomeres in T and B cells. Nat Rev Immunol 2002; 2:699-706. (Pubitemid 37328727)
6. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 2003; 23:842-6. (Pubitemid 36566175)
7. Brouilette SW, Moore JS, McMahon AD, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007; 369:107-14. (Pubitemid 46073129)
8. Farzaneh-Far R, Cawthon RM, Na B, Browner WS, Schiller NB, Whooley MA. Prognostic value of leukocyte telomere length in patients with stable coronary artery disease: data from the Heart and Soul Study. Arterioscler Thromb Vasc Biol 2008; 28:1379-84.
9. Fitzpatrick AL, Kronmal RA, Gardner JP, et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol 2007; 165:14-21. (Pubitemid 46026204)
10. Takata Y, Kikukawa M, Hanyu H, et al. Association between ApoE phenotypes and telomere erosion in Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2012; 67:330-5.
11. Lof-Ohlin ZM, Hagnelius NO, Nilsson TK. Relative telomere length in patients with late-onset Alzheimer's dementia or vascular dementia. Neuroreport 2008; 19:1199-202.
12. Panossian LA, Porter VR, Valenzuela HF, et al. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging 2003; 24:77-84. (Pubitemid 35454145)
13. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43: 405-13. (Pubitemid 16213265)
14. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279:349-52. (Pubitemid 28063364)
15. Datta A, Bellon M, Sinha-Datta U, et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 2006; 108:1021-9. (Pubitemid 44154640)
16. Liu X, Inomata M, Ogawara T, Saneyoshi M, Yamaguchi T. Telomere shortening in human HL60 cells by treatment with 3′-azido-2′, 3′- dideoxynucleosides and telomerase inhibition by their 5′-triphosphates. Nucleosides Nucleotides Nucleic Acids 2007; 26:1067-71. (Pubitemid 350223305)
17. Liu X, Takahashi H, Harada Y, et al. 3′-Azido-2′,3′- dideoxynucleoside 5′-triphosphates inhibit telomerase activity in vitro, and the corresponding nucleosides cause telomere shortening in human HL60 cells. Nucleic Acids Res 2007; 35:7140-9.
18. Murakami J, Nagai N, Shigemasa K, Ohama K. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur J Cancer 1999; 35:1027-34. (Pubitemid 29277142)
19. Olivero OA, Fernandez JJ, Antiochos BB, Wagner JL, St Claire ME, Poirier MC. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr 2002; 29:323-9. (Pubitemid 34288884)
20. Rossi A, Russo G, Puca A, et al. The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells. Int J Cancer 2009; 125:235-43.
21. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996; 16:53-65. (Pubitemid 126506950)
22. Wolthers KC, Otto SA, Wisman GB, et al. Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection. Blood 1999; 93:1011-9. (Pubitemid 29067866)
23. Wege H, Chui MS, Le HT, Tran JM, Zern MA. SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Res 2003; 31:E3-3.
24. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011-5.
25. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30:e47.
26. Cooper DA, Matthews G. Tenofovir. In: Crowe SM, Mills J, eds. Kucers' The Use of Antibiotics, 6th Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. Hodder Arnold, 2010:2613-26.
27. Back DJ, Burger DM, Flexner CW, Gerber JG. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J Acquir Immune Defic Syndr 2005; 39(Suppl 1):S1-23, quiz S24-25.
28. Hazen R, Lanier ER. Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr 2003; 32:255-8. (Pubitemid 36331696)
29. Kumar PN, Sweet DE, McDowell JA, et al. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 1999; 43:603-8. (Pubitemid 29109526)
30. Taylor DL, Ahmed PS, Tyms AS, et al. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2′-deoxy-3′-oxa-4′-thiocytidine, dOTC]. Antivir Chem Chemother 2000; 11:291-301. (Pubitemid 30608570)
31. Bruning A, Burger P, Gingelmaier A, Mylonas I. The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells. Invest New Drugs 2012; 30:1389-95.
32. Enomoto L, Anderson PL, Li S, Edelstein CL, Weinberg A. Effect of nucleoside and nucleotide analog reverse transcriptase inhibitors on cell-mediated immune functions. AIDS Res Hum Retroviruses 2011; 27:47-55.
33. Palmer LD, Weng N, Levine BL, June CH, Lane HC, Hodes RJ. Telomere length, telomerase activity, and replicative potential in HIV infection: analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins. J Exp Med 1997; 185:1381-6. (Pubitemid 27172918)
34. Lichterfeld M, Mou D, Cung TD, et al. Telomerase activity of HIV-1- specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood 2008; 112:3679-87.
35. Rickabaugh TM, Kilpatrick RD, Hultin LE, et al. The dual impact of HIV-1 infection and aging on naive CD4 T-cells: additive and distinct patterns of impairment. PLoS One 2011; 6:e16459.
36. Hearps AC, Maisa A, Cheng WJ, et al. HIV infection induces agerelated changes to monocytes and innate immune activation in young males which persist despite cART. AIDS 2012; 26:843-53.
37. Franzese O, Adamo R, Pollicita M, et al. Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1). J Med Virol 2007; 79:639-46. (Pubitemid 46564364)
38. Imam T, Jitratkosol MH, Soudeyns H, et al. Leukocyte telomere length in HIV-infected pregnant women treated with antiretroviral drugs during pregnancy and their uninfected infants. J Acquir Immune Defic Syndr 2012; 60:495-502.
39. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-2.
40. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997; 3: 1271-4. (Pubitemid 27508830)
41. Slatter TL, Tan X, Yuen YC, et al. The alternative lengthening of telomeres pathway may operate in non-neoplastic human cells. J Pathol 2012; 226:509-18.
42. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010; 11:319-30.
43. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003; 101:2711-20. (Pubitemid 36857634)
44. Comandini FA, Lombardi A, Saponiero A, Bonmassar E. Saquinavir up-regulates telomerase activity in lymphocytes activated with monoclonal antibodies against CD3/CD28. J Chemother 2001; 13:384-8. (Pubitemid 32721631)
45. Franzese O, Lombardi A, Comandini A, et al. Effect of Saquinavir on proliferation and telomerase activity of human peripheral blood mononuclear cells. Life Sci 2001; 69:1509-20. (Pubitemid 32786724)
46. McGrath M, Wong JY, Michaud D, Hunter DJ, De Vivo I. Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 2007; 16:815-9. (Pubitemid 46650587)
47. Spyridopoulos I, Hoffmann J, Aicher A, et al. Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity. Circulation 2009; 120:1364-72.
48. Werner C, Furster T, Widmann T, et al. Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. Circulation 2009; 120:2438-47.